Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial
Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to M...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sheriff, Abraar [verfasserIn] Rameshkumar, Ramachandran [verfasserIn] Chidambaram, Muthu [verfasserIn] Maulik, Kaushik [verfasserIn] Kumar, Routhu Santhosh [verfasserIn] Jamal, Atahar [verfasserIn] Bhowmick, Rohit [verfasserIn] Biswal, Niranjan [verfasserIn] Mahadevan, Subramanian [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Indian Academy of Pediatrics 2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Pediatrics - Springer-Verlag, 2010, 58(2021), 7 vom: 19. Feb., Seite 624-630 |
|---|---|
| Übergeordnetes Werk: |
volume:58 ; year:2021 ; number:7 ; day:19 ; month:02 ; pages:624-630 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13312-021-2256-9 |
|---|
| Katalog-ID: |
SPR044757026 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044757026 | ||
| 003 | DE-627 | ||
| 005 | 20230519182817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210806s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13312-021-2256-9 |2 doi | |
| 035 | |a (DE-627)SPR044757026 | ||
| 035 | |a (SPR)s13312-021-2256-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sheriff, Abraar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Indian Academy of Pediatrics 2021 | ||
| 520 | |a Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. | ||
| 650 | 4 | |a In-hospital cardiac arrest |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rameshkumar, Ramachandran |e verfasserin |4 aut | |
| 700 | 1 | |a Chidambaram, Muthu |e verfasserin |4 aut | |
| 700 | 1 | |a Maulik, Kaushik |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Routhu Santhosh |e verfasserin |4 aut | |
| 700 | 1 | |a Jamal, Atahar |e verfasserin |4 aut | |
| 700 | 1 | |a Bhowmick, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Biswal, Niranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Mahadevan, Subramanian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Pediatrics |d Springer-Verlag, 2010 |g 58(2021), 7 vom: 19. Feb., Seite 624-630 |w (DE-627)SPR031274943 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2021 |g number:7 |g day:19 |g month:02 |g pages:624-630 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13312-021-2256-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_72 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_131 | ||
| 912 | |a GBV_ILN_160 | ||
| 912 | |a GBV_ILN_376 | ||
| 912 | |a GBV_ILN_607 | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2021 |e 7 |b 19 |c 02 |h 624-630 | ||
| author_variant |
a s as r r rr m c mc k m km r s k rs rsk a j aj r b rb n b nb s m sm |
|---|---|
| matchkey_str |
sheriffabraarrameshkumarramachandranchid:2021----:pnprnpuvspesnspnprnpupaeoneitiitnieaentadoumnrrssiainrn |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1007/s13312-021-2256-9 doi (DE-627)SPR044757026 (SPR)s13312-021-2256-9-e DE-627 ger DE-627 rakwb eng Sheriff, Abraar verfasserin aut Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2021 Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. In-hospital cardiac arrest (dpeaa)DE-He213 Rameshkumar, Ramachandran verfasserin aut Chidambaram, Muthu verfasserin aut Maulik, Kaushik verfasserin aut Kumar, Routhu Santhosh verfasserin aut Jamal, Atahar verfasserin aut Bhowmick, Rohit verfasserin aut Biswal, Niranjan verfasserin aut Mahadevan, Subramanian verfasserin aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 58(2021), 7 vom: 19. Feb., Seite 624-630 (DE-627)SPR031274943 nnns volume:58 year:2021 number:7 day:19 month:02 pages:624-630 https://dx.doi.org/10.1007/s13312-021-2256-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 58 2021 7 19 02 624-630 |
| spelling |
10.1007/s13312-021-2256-9 doi (DE-627)SPR044757026 (SPR)s13312-021-2256-9-e DE-627 ger DE-627 rakwb eng Sheriff, Abraar verfasserin aut Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2021 Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. In-hospital cardiac arrest (dpeaa)DE-He213 Rameshkumar, Ramachandran verfasserin aut Chidambaram, Muthu verfasserin aut Maulik, Kaushik verfasserin aut Kumar, Routhu Santhosh verfasserin aut Jamal, Atahar verfasserin aut Bhowmick, Rohit verfasserin aut Biswal, Niranjan verfasserin aut Mahadevan, Subramanian verfasserin aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 58(2021), 7 vom: 19. Feb., Seite 624-630 (DE-627)SPR031274943 nnns volume:58 year:2021 number:7 day:19 month:02 pages:624-630 https://dx.doi.org/10.1007/s13312-021-2256-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 58 2021 7 19 02 624-630 |
| allfields_unstemmed |
10.1007/s13312-021-2256-9 doi (DE-627)SPR044757026 (SPR)s13312-021-2256-9-e DE-627 ger DE-627 rakwb eng Sheriff, Abraar verfasserin aut Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2021 Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. In-hospital cardiac arrest (dpeaa)DE-He213 Rameshkumar, Ramachandran verfasserin aut Chidambaram, Muthu verfasserin aut Maulik, Kaushik verfasserin aut Kumar, Routhu Santhosh verfasserin aut Jamal, Atahar verfasserin aut Bhowmick, Rohit verfasserin aut Biswal, Niranjan verfasserin aut Mahadevan, Subramanian verfasserin aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 58(2021), 7 vom: 19. Feb., Seite 624-630 (DE-627)SPR031274943 nnns volume:58 year:2021 number:7 day:19 month:02 pages:624-630 https://dx.doi.org/10.1007/s13312-021-2256-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 58 2021 7 19 02 624-630 |
| allfieldsGer |
10.1007/s13312-021-2256-9 doi (DE-627)SPR044757026 (SPR)s13312-021-2256-9-e DE-627 ger DE-627 rakwb eng Sheriff, Abraar verfasserin aut Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2021 Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. In-hospital cardiac arrest (dpeaa)DE-He213 Rameshkumar, Ramachandran verfasserin aut Chidambaram, Muthu verfasserin aut Maulik, Kaushik verfasserin aut Kumar, Routhu Santhosh verfasserin aut Jamal, Atahar verfasserin aut Bhowmick, Rohit verfasserin aut Biswal, Niranjan verfasserin aut Mahadevan, Subramanian verfasserin aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 58(2021), 7 vom: 19. Feb., Seite 624-630 (DE-627)SPR031274943 nnns volume:58 year:2021 number:7 day:19 month:02 pages:624-630 https://dx.doi.org/10.1007/s13312-021-2256-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 58 2021 7 19 02 624-630 |
| allfieldsSound |
10.1007/s13312-021-2256-9 doi (DE-627)SPR044757026 (SPR)s13312-021-2256-9-e DE-627 ger DE-627 rakwb eng Sheriff, Abraar verfasserin aut Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2021 Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. In-hospital cardiac arrest (dpeaa)DE-He213 Rameshkumar, Ramachandran verfasserin aut Chidambaram, Muthu verfasserin aut Maulik, Kaushik verfasserin aut Kumar, Routhu Santhosh verfasserin aut Jamal, Atahar verfasserin aut Bhowmick, Rohit verfasserin aut Biswal, Niranjan verfasserin aut Mahadevan, Subramanian verfasserin aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 58(2021), 7 vom: 19. Feb., Seite 624-630 (DE-627)SPR031274943 nnns volume:58 year:2021 number:7 day:19 month:02 pages:624-630 https://dx.doi.org/10.1007/s13312-021-2256-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 58 2021 7 19 02 624-630 |
| language |
English |
| source |
Enthalten in Indian Pediatrics 58(2021), 7 vom: 19. Feb., Seite 624-630 volume:58 year:2021 number:7 day:19 month:02 pages:624-630 |
| sourceStr |
Enthalten in Indian Pediatrics 58(2021), 7 vom: 19. Feb., Seite 624-630 volume:58 year:2021 number:7 day:19 month:02 pages:624-630 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
In-hospital cardiac arrest |
| isfreeaccess_bool |
false |
| container_title |
Indian Pediatrics |
| authorswithroles_txt_mv |
Sheriff, Abraar @@aut@@ Rameshkumar, Ramachandran @@aut@@ Chidambaram, Muthu @@aut@@ Maulik, Kaushik @@aut@@ Kumar, Routhu Santhosh @@aut@@ Jamal, Atahar @@aut@@ Bhowmick, Rohit @@aut@@ Biswal, Niranjan @@aut@@ Mahadevan, Subramanian @@aut@@ |
| publishDateDaySort_date |
2021-02-19T00:00:00Z |
| hierarchy_top_id |
SPR031274943 |
| id |
SPR044757026 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR044757026</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182817.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210806s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13312-021-2256-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044757026</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13312-021-2256-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sheriff, Abraar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Academy of Pediatrics 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">In-hospital cardiac arrest</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rameshkumar, Ramachandran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chidambaram, Muthu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maulik, Kaushik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Routhu Santhosh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jamal, Atahar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhowmick, Rohit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biswal, Niranjan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mahadevan, Subramanian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Pediatrics</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">58(2021), 7 vom: 19. Feb., Seite 624-630</subfield><subfield code="w">(DE-627)SPR031274943</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:58</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:7</subfield><subfield code="g">day:19</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:624-630</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13312-021-2256-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_131</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_160</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_376</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_607</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">58</subfield><subfield code="j">2021</subfield><subfield code="e">7</subfield><subfield code="b">19</subfield><subfield code="c">02</subfield><subfield code="h">624-630</subfield></datafield></record></collection>
|
| author |
Sheriff, Abraar |
| spellingShingle |
Sheriff, Abraar misc In-hospital cardiac arrest Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial |
| authorStr |
Sheriff, Abraar |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR031274943 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial In-hospital cardiac arrest (dpeaa)DE-He213 |
| topic |
misc In-hospital cardiac arrest |
| topic_unstemmed |
misc In-hospital cardiac arrest |
| topic_browse |
misc In-hospital cardiac arrest |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Pediatrics |
| hierarchy_parent_id |
SPR031274943 |
| hierarchy_top_title |
Indian Pediatrics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR031274943 |
| title |
Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial |
| ctrlnum |
(DE-627)SPR044757026 (SPR)s13312-021-2256-9-e |
| title_full |
Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial |
| author_sort |
Sheriff, Abraar |
| journal |
Indian Pediatrics |
| journalStr |
Indian Pediatrics |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
624 |
| author_browse |
Sheriff, Abraar Rameshkumar, Ramachandran Chidambaram, Muthu Maulik, Kaushik Kumar, Routhu Santhosh Jamal, Atahar Bhowmick, Rohit Biswal, Niranjan Mahadevan, Subramanian |
| container_volume |
58 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sheriff, Abraar |
| doi_str_mv |
10.1007/s13312-021-2256-9 |
| author2-role |
verfasserin |
| title_sort |
epinephrine plus vasopressin vs epinephrine plus placebo in pediatric intensive care unit cardiopulmonary resuscitation: a randomized double blind controlled clinical trial |
| title_auth |
Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial |
| abstract |
Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. © Indian Academy of Pediatrics 2021 |
| abstractGer |
Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. © Indian Academy of Pediatrics 2021 |
| abstract_unstemmed |
Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo. © Indian Academy of Pediatrics 2021 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 |
| container_issue |
7 |
| title_short |
Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial |
| url |
https://dx.doi.org/10.1007/s13312-021-2256-9 |
| remote_bool |
true |
| author2 |
Rameshkumar, Ramachandran Chidambaram, Muthu Maulik, Kaushik Kumar, Routhu Santhosh Jamal, Atahar Bhowmick, Rohit Biswal, Niranjan Mahadevan, Subramanian |
| author2Str |
Rameshkumar, Ramachandran Chidambaram, Muthu Maulik, Kaushik Kumar, Routhu Santhosh Jamal, Atahar Bhowmick, Rohit Biswal, Niranjan Mahadevan, Subramanian |
| ppnlink |
SPR031274943 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13312-021-2256-9 |
| up_date |
2024-07-04T02:12:45.847Z |
| _version_ |
1803612759889281024 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR044757026</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182817.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210806s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13312-021-2256-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044757026</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13312-021-2256-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sheriff, Abraar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Academy of Pediatrics 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To compare the efficacy of epinephrine plus vasopressin vs epinephrine plus placebo in the pediatric intensive care unit (PICU) cardiopulmonary resuscitation (CPR). Design Randomized, double-blind controlled clinical trial. Setting PICU in a tertiary care institute from February, 2019 to May, 2020. Participants Children aged one month to 13 years who required CPR during PICU stay. Patients in whom vascular access was not available or return of spontaneous circulation (ROSC) was achieved by defibrillation without epinephrine were excluded. Intervention Patients were randomized to receive vasopressin 0.1 mL per kg (=0.8 unit per kg) or placebo (0.1 mL per kg normal saline) in addition to epinephrine (1:10000) 0.1 mL per kg. The drugs were given as bolus doses every three minutes until the ROSC or up to a maximum of five doses, whichever was earlier. Outcome Measure The primary outcome was the proportion of patients who achieved ROSC. The secondary outcomes were survival rate and functional status (at 24-hour, PICU, hospital, and 90-day post-discharge), need for organ supports, length of stay (PICU and hospital), and adverse effect(s) of the study drugs. Results 90 patients (epinephrine plus vasopressin group, n=45 and epinephrine plus placebo group, n=45) were analyzed on intention-to-treat basis. There was no significant difference in the primary outcome between epinephrine plus vasopressin (n=25, 55.5%) and epinephrine plus placebo groups (n=24, 53.3%) (Relative risk 1.04, 95% CI 0.71 to 1.52). There was no significant difference in survival rate at 24-hour (n=7, 15.6% vs. n=8, 17.8%), at PICU, hospital, and 90-day post-discharge (n=1, 2.2% vs n=1, 2.2%). There was no difference in other secondary outcomes. No trial drug-related serious adverse events were observed. Conclusion A combination of epinephrine plus vasopressin did not improve the rate of return of spontaneous circulation in the pediatric intensive care unit cardiopulmonary resuscitation as compared with epinephrine plus placebo.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">In-hospital cardiac arrest</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rameshkumar, Ramachandran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chidambaram, Muthu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maulik, Kaushik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Routhu Santhosh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jamal, Atahar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhowmick, Rohit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biswal, Niranjan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mahadevan, Subramanian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Pediatrics</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">58(2021), 7 vom: 19. Feb., Seite 624-630</subfield><subfield code="w">(DE-627)SPR031274943</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:58</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:7</subfield><subfield code="g">day:19</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:624-630</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13312-021-2256-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_131</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_160</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_376</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_607</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">58</subfield><subfield code="j">2021</subfield><subfield code="e">7</subfield><subfield code="b">19</subfield><subfield code="c">02</subfield><subfield code="h">624-630</subfield></datafield></record></collection>
|
| score |
7.399205 |